Author Review β inspect what researchers actually reported
Aggregate an author's papers' raw data, methods, conflicts, and reproducibility cues.
Press Enter β΅ to lookup
Explore by Goal
"The scientific man does not aim at an immediate result. He does not expect that his advanced ideas will be readily taken up. His work is like that of the planter - for the future. His duty is to lay the foundation for those who are to come, and point the way."
- Nikola Tesla
Quick Explanation
Copied
Xuan Wang β scientific strength check
Across the provided publication record, the strongest signal is methodologically rigorous work in computational biology/genomics (e.g., promoter inference with cross-species evidence, immunotherapy biomarkers integrating multi-omic signatures), plus several experimental/biological mechanistic studies with multi-omics and in vivo/ex vivo validation (e.g., USP14βPARP1βMIC-A/B axis in glioma, SAMHD1 dynamics during chronic HIV-1 infection, armored CAR-T mechanisms)
Long Explanation
Author Review: Xuan Wang
This review is strictly grounded in the publication metadata and extracted study details you provided (and the DOIs supplied therein). Because no author-level full-text list, lab history, or disambiguated author profile was provided, the review focuses on the scientific quality signals present in the supplied paper set (methods, validation depth, bias controls, and reproducibility signals), not on identity certainty.
Visual evidence snapshots (from your provided extracted data)
AUC values are reported as an extracted range for models that reported AUC in the synthesis .
IU1 inhibition of tumor growth is extracted as ~80% in C57BL/6J and ~50% in BALB/c-nude .
Note: the extracted summary does not include statistical uncertainty, endpoints, or replication details; confidence depends on full paper access.
Values are extracted from the CT-based multicenter study summary .
Bias risks are noted in the extracted limitations (retrospective convenience sampling, reader bias, center harmonization effects) .
Scientific strengths observed in the provided record
1) Methodological integration and validation depth (multi-omic / multi-modal)
Mechanistic cancer immunology work connects a deubiquitinase axis (USP14) to antigen-presentation machinery readouts (MIC-A/B) and CD8 killing, using inhibitor/CRISPR perturbations, protein-pathway assays, multi-omics (RNA-seq/scRNA-seq/spatial transcriptomics), and both murine and human correlation elements .
Translational signal integration appears in computational immunotherapy biomarker work: TIGS combines antigen-processing machinery signatures (APS) with mutation burden proxies, then benchmarks performance across pan-cancer training (TCGA) and independent ICI cohorts, reporting quantitative associations and ROC/correlation results .
2) Computational rigor signals in genomics resource-building
Promoter/TSS resource-building shows explicit performance measurement (sensitivity/specificity across multiple test sets and promoter classes) and a defined integration strategy (transcript evidence + cross-species conservation) .
3) Evidence-aware bias handling (explicit risk-of-bias frameworks in synthesis)
The Kawasaki disease IVIG-resistance review explicitly applies PROBAST risk-of-bias assessment and identifies widespread methodological risks (analysis/participants domains) and limited external validation .
Scientific weak points / uncertainty sources
Over-reliance on proxies and correlative inference in several biology/cancer studies. For TIGS, APS is derived from mRNA expression (not protein/function), and the extracted limitations explicitly note incomplete protein-level validation .
Generalizability risks. In the USP14βPARP1βMIC-A/B glioma work, limitations include predominant GL261 model dependence and uncertainty about CNS pharmacokinetics/toxicity and durability across glioma subtypes .
Retrospective/convenience sampling and reader/case-selection bias (imaging biomarker study). The TB CT cavitation study is retrospective and includes potential biases: uneven geographic distribution, convenience sampling, reader bias, harmonization issues, and surrogate variables for chronicity .
Reproducibility constraints from data access or proprietary dependencies. Some bioinformatics/biomedical works in your dataset reference data hosted in external repositories or state βavailable on requestβ; without direct access here, reproducibility confidence cannot be maximal (even when methods are described). Example: TIGS code is on GitHub/archived , but some other studies provide partial access statements only.
Author disambiguation risk. βXuan Wangβ can be a common name; your OpenAlex query results were not disambiguated to the same individual with high confidence. Therefore, any inference that βthis authorβ authored all listed publications would be scientifically unsafe. In this review, I treat the provided DOI set as the object of assessment, not as a guaranteed all-by-one author identity.
Cross-domain competence pattern (what the record suggests, cautiously)
The provided set spans computational genomics resource construction (promoters/TSS) , immunotherapy biomarker modeling from pan-cancer datasets , and immunology/cancer mechanistic studies with perturbation biology and multi-omics .
The record also includes review-level synthesis and diverse applied methods; this can indicate breadth, but breadth can also reflect dilution of specialization. Without the authorβs full CV and contribution statements, βdepth vs breadthβ remains uncertain.
What would most improve scientific confidence (falsification targets)
For biomarker modeling (e.g., TIGS): show prospective, blinded validation where protein-level antigen processing capacity is measured directly, and where confounding (tumor purity, treatment history, assay/platform differences) is controlled .
For mechanistic immunology: demonstrate durability and generalizability across multiple glioma models and verify CNS delivery/toxicity for the specific target axis (USP14-PARP1-MIC-A/B) .
For imaging biomarkers: validate with prospective cohorts using standardized imaging and blinded readers, and quantify how much performance survives removing disease-history information (if the model relies on it) .
Overall scientific assessment (based on the provided paper set only)
High-level verdict: The record shows several strong scientific signalsβquantitative evaluation in computational resource work , explicit risk-of-bias assessment in a synthesis , and mechanistic immunology with multi-omics perturbation validation .
Confidence is limited by two factors you may want to address: (i) author disambiguation for common names, and (ii) the review set includes many topics beyond strict biology (e.g., computer vision, marine LLM), so the biological βdepthβ question cannot be fully answered without the full bibliography and contribution statements.
Feedback:
Updated: April 03, 2026
BGPT Author Review
Scientific Quality
70%
The provided record contains multiple strong methodological signals (quantitative model evaluation, explicit risk-of-bias framework use, and perturbation-based mechanistic biology with multi-omics). However, several studies rely on proxies (e.g., mRNA for antigen presentation), have generalizability risks (model-system dependence), and include design limitations common in translational work (retrospective cohorts, limited prospective validation). Biggest scientific red flag is uncertainty about author identity/disambiguation for βXuan Wang,β plus incomplete access details limiting reproducibility confidence for some items.
Communication Quality
60%
Based on the extracted summaries alone, communications appear fairly structured (one-sentence summaries, methods/results/limitations). But the material provided is not the authorβs writing itself; thus assessment is indirect. Several summaries omit key uncertainty details (CIs, effect sizes beyond headline values), which would reduce clarity for expert readers.
Author Novelty
70%
Novelty is moderate-to-high where the extracted work proposes new integrated frameworks (e.g., combining transcript evidence and cross-species conservation for promoter prediction; TIGS combining antigen presentation with mutation burden). But novelty cannot be fully judged without knowing what portion of each work is genuinely new vs incremental improvements and without the full paper context.
Scientific Rigor
70%
Rigor is strong in the presence of explicit benchmarking, quantified performance, and defined bias assessment (PROBAST). Mechanistic biology sections also appear rigorous (perturbations + functional readouts). Yet rigor is weakened when validation is indirect (mRNA proxies), when reliance on specific animal models is heavy, or when cohorts are retrospective/convenience-based without strong controls.
I would parse the extracted numeric summaries (AUC ranges, tumor inhibition %, cavity prevalence) into a tidy table and generate reproducible Plotly figures for sensitivity/specificity and effect-size comparison.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
βThe AUC range (0.672β0.891) alone proves IVIG-resistance prediction models are clinically usable.β This is unlikely because the synthesis indicates widespread high risk of bias and limited external validation, so AUC without robust design doesnβt establish clinical utility .
βCavity burden on CT causally determines drug resistance phenotype.β This is unlikely; retrospective design and surrogate markers/history and imaging interpretation variability mean causality is not established .
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion